Immunome Inc.(IMNM)Stock Analysis

IMNM Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Immunome Inc. (IMNM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IMNM at 5.8/100 on a 32-signal composite quality model, placing it at rank #2,844 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (1.1) and profitability (1.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Immunome Inc. reports net income of $-53.8M, free cash flow of $-61.6M. Top institutional holders of IMNM by reported 13-F value include FMR, BlackRock,, Redmile Group,, based on the most recent SEC filings. IMNM trades on the Nasdaq exchange and files with the SEC under CIK 1472012. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMNM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Immunome Inc. directly from SEC EDGAR. Immunome Inc.'s 13F Pro composite quality score has ranged between 6 and 37 since 2024, currently 5.8 — a declining long-term trajectory across 32 quarterly and live scoring snapshots.